FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vaccines (Basel) / Vaccination and Control Methods of West Nile Virus Infection...
Vaccines2024; 12(5); 485; doi: 10.3390/vaccines12050485

Vaccination and Control Methods of West Nile Virus Infection in Equids and Humans.

Abstract: West Nile virus (WNV) is capable of causing severe neurologic disease in both humans and equines, making it a disease of importance in both human medicine and veterinary medicine. No targeted treatments exist for WNV infection in either humans or equines. Infection is treated symptomatically through management of symptoms like fever and seizures. As treatment for WNV is purely supportive, the response to WNV has focused primarily on methods of disease prevention. To this end, research efforts have yielded several effective vaccines for equine use as well as numerous conventional mosquito control techniques. Even with the implementation of these techniques, disease caused by WNV remains a concern since no human vaccine exists. Due to the lack of a human vaccine, novel preventative strategies are under active research and development. Of these strategies, some of the most conceptually promising are techniques using genetically modified mosquitoes, addressing the disease at the vector level with minimal ecological side effects. Taken together, the use of combined, synergistic methods, such as physical barriers, transgenic mosquitoes, and immunological targets, will be the best way to prevent WNV disease.
Get Full Text
Publication Date: 2024-05-01 PubMed ID: 38793736PubMed Central: PMC11125624DOI: 10.3390/vaccines12050485Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Review

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

Overview

  • This research article reviews the current vaccination and control methods for West Nile Virus (WNV) infection affecting both equids (horses) and humans.
  • It highlights the lack of targeted treatments, the availability of equine vaccines, existing mosquito control strategies, and emerging novel approaches, especially for human prevention.

Understanding West Nile Virus and Its Impact

  • West Nile Virus (WNV) is a significant pathogen causing severe neurological illness.
  • Both humans and equids are susceptible to infection, making it a concern in both human and veterinary medicine.
  • Symptoms in infected individuals may include fever, seizures, and other neurological issues.
  • No specific antiviral treatment exists, so management focuses on symptomatic relief.

Current Treatment Approaches

  • Treatment for WNV infection is entirely supportive since no targeted antiviral therapies are available.
  • Symptomatic treatment includes managing fever, seizures, and other neurological symptoms to improve patient outcomes.
  • This approach is applied similarly to both human and equine infections.

Vaccination in Equids

  • Several effective vaccines have been developed for the prevention of WNV infection in horses.
  • These vaccines help reduce the incidence and severity of neurological disease in equids.
  • Widespread use of these vaccines is a key preventive measure in veterinary medicine.
  • Despite vaccination efforts, outbreaks in equine populations still occur, emphasizing the need for continued vigilance.

Conventional Mosquito Control Methods

  • Mosquitoes are the primary vectors transmitting WNV between birds, equids, and humans.
  • Traditional mosquito control practices include physical barriers (e.g., window screens, nets), insecticide use, and habitat reduction (eliminating standing water).
  • These methods help reduce mosquito populations and limit disease transmission.
  • Mosquito control is a cornerstone of both human and equine WNV prevention efforts.

Challenges in Human WNV Prevention

  • Unlike equids, currently no licensed vaccine exists for human use against WNV.
  • This absence of a human vaccine makes prevention reliant on mosquito control and personal protective strategies.
  • Human disease remains a public health concern, necessitating the continued development of new prevention strategies.

Emerging Novel Preventative Strategies

  • Research is focused on innovative approaches to prevent WNV transmission, addressing the virus at the mosquito vector level.
  • One promising approach is the use of genetically modified (transgenic) mosquitoes designed to reduce vector competence or population size.
  • These strategies aim to minimize disease spread while having limited ecological side effects compared to widespread insecticide use.
  • Other research areas include enhancing immunological targets and combining various control methods for a synergistic effect.

Integrated Prevention Approach

  • The article emphasizes that no single intervention is sufficient; a combination of methods offers the best protection.
  • Physical barriers prevent mosquito bites directly at the individual level.
  • Transgenic mosquitoes could reduce virus transmission in the environment.
  • Immunological measures (e.g., vaccines in equids, potential future human vaccines) target the host’s susceptibility.
  • Combining these approaches is expected to enhance overall effectiveness in controlling WNV disease.

Cite This Article

APA
Cendejas PM, Goodman AG. (2024). Vaccination and Control Methods of West Nile Virus Infection in Equids and Humans. Vaccines (Basel), 12(5), 485. https://doi.org/10.3390/vaccines12050485

Publication

Vaccines
ISSN: 2076-393X
NlmUniqueID: 101629355
Country: Switzerland
Language: English
Volume: 12
Issue: 5
PII: 485

Researcher Affiliations

Cendejas, Parker M
  • Doctor of Veterinary Medicine Graduate Program, Washington State University, Pullman, WA 99164, USA.
Goodman, Alan G
  • School of Molecular Biosciences, Washington State University, Pullman, WA 99164, USA.
  • Paul G. Allen School of Global Health, College of Veterinary Medicine, Washington State University, Pullman, WA 99164, USA.

Conflict of Interest Statement

The authors declare no conflict of interest.

References

This article includes 59 references
  1. Colpitts TM, Conway MJ, Montgomery RR, Fikrig E. West Nile Virus: Biology, transmission, and human infection.. Clin. Microbiol. Rev. 2012;25:635–648.
    doi: 10.1128/cmr.00045-12pmc: PMC3485754pubmed: 23034323google scholar: lookup
  2. Orba Y, Hang’ombe BM, Mweene AS, Wada Y, Anindita PD, Phongphaew W, Qiu Y, Kajihara M, Mori-Kajihara A, Eto Y. First isolation of West Nile virus in Zambia from mosquitoes.. Transbound. Emerg. Dis. 2018;65:933–938.
    doi: 10.1111/tbed.12888pubmed: 29722174google scholar: lookup
  3. Hadler JL, Patel D, Bradley K, Hughes JM, Blackmore C, Etkind P, Kan L, Getchell J, Blumenstock J, Engel J. National capacity for surveillance, prevention, and control of West Nile virus and other arbovirus infections--United States, 2004 and 2012.. MMWR Morb. Mortal. Wkly. Rep. 2014;63:281–284.
    pmc: PMC5779350pubmed: 24699764
  4. Miller MJ, Loaiza JR. Geographic expansion of the invasive mosquito Aedes albopictus across Panama--implications for control of dengue and Chikungunya viruses.. PLoS Neglected Trop. Dis. 2015;9:e0003383.
    doi: 10.1371/journal.pntd.0003383pmc: PMC4287627pubmed: 25569303google scholar: lookup
  5. Ahlers LRH, Goodman AG. The Immune Responses of the Animal Hosts of West Nile Virus: A Comparison of Insects, Birds, and Mammals.. Front. Cell. Infect. Microbiol. 2018;8:96.
    doi: 10.3389/fcimb.2018.00096pmc: PMC5891621pubmed: 29666784google scholar: lookup
  6. Bowen RA, Nemeth NM. Experimental infections with West Nile virus.. Curr. Opin. Infect. Dis. 2007;20:293–297.
    doi: 10.1097/QCO.0b013e32816b5cadpubmed: 17471040google scholar: lookup
  7. Giesen C, Herrador Z, Fernandez-Martinez B, Figuerola J, Gangoso L, Vazquez A, Gómez-Barroso D. A systematic review of environmental factors related to WNV circulation in European and Mediterranean countries.. One Health 2023;16:100478.
    doi: 10.1016/j.onehlt.2022.100478pmc: PMC10288031pubmed: 37363246google scholar: lookup
  8. D’Amore C, Grimaldi P, Ascione T, Conti V, Sellitto C, Franci G, Kafil SH, Pagliano P. West Nile Virus diffusion in temperate regions and climate change. A systematic review.. Infez Med. 2022;31:20–30.
    doi: 10.53854/liim-3101-4pmc: PMC9994819pubmed: 36908379google scholar: lookup
  9. Paré J, Moore A. West Nile virus in horses—What do you need to know to diagnose the disease?. Can. Vet. J. 2018;59:1119–1120.
    pmc: PMC6135266pubmed: 30510321
  10. Schwarz ER, Long MT. Comparison of West Nile Virus Disease in Humans and Horses: Exploiting Similarities for Enhancing Syndromic Surveillance.. Viruses 2023;15:1230.
    doi: 10.3390/v15061230pmc: PMC10303507pubmed: 37376530google scholar: lookup
  11. Government of Canada West Nile Virus: Surveillance. [(accessed on 22 April 2024)]. Available online: https://inspection.canada.ca/animal-health/terrestrial-animals/diseases/immediately-notifiable/west-nile-virus/surveillance/eng/1346131121021/1346131213336.
  12. Castro-Jorge LA, Siconelli MJL, Ribeiro BDS, Moraes FM, Moraes JB, Agostinho MR, Klein TM, Floriano VG, Fonseca B. West Nile virus infections are here! Are we prepared to face another flavivirus epidemic?. Rev. Soc. Bras. Med. Trop. 2019;52:e20190089.
    doi: 10.1590/0037-8682-0089-2018pubmed: 30942263google scholar: lookup
  13. Desanti-Consoli H, Bouillon J, Chapuis RJJ. Equids’ Core Vaccines Guidelines in North America: Considerations and Prospective.. Vaccines 2022;10:398.
    doi: 10.3390/vaccines10030398pmc: PMC8955191pubmed: 35335029google scholar: lookup
  14. Komar N, Langevin S, Hinten S, Nemeth N, Edwards E, Hettler D, Davis B, Bowen R, Bunning M. Experimental infection of North American birds with the New York 1999 strain of West Nile virus.. Emerg. Infect. Dis. 2003;9:311–322.
    doi: 10.3201/eid0903.020628pmc: PMC2958552pubmed: 12643825google scholar: lookup
  15. Kramer LD, Bernard KA. West Nile virus infection in birds and mammals.. Ann. N. Y. Acad. Sci. 2001;951:84–93.
    doi: 10.1111/j.1749-6632.2001.tb02687.xpubmed: 11797807google scholar: lookup
  16. Reed KD, Meece JK, Henkel JS, Shukla SK. Birds, migration and emerging zoonoses: West nile virus, lyme disease, influenza A and enteropathogens.. Clin. Med. Res. 2003;1:5–12.
    doi: 10.3121/cmr.1.1.5pmc: PMC1069015pubmed: 15931279google scholar: lookup
  17. Nemeth NM, Kratz GE, Bates R, Scherpelz JA, Bowen RA, Komar N. Naturally induced humoral immunity to West Nile virus infection in raptors.. Ecohealth 2008;5:298–304.
    doi: 10.1007/s10393-008-0183-zpubmed: 18677535google scholar: lookup
  18. Nemeth NM, Oesterle PT, Bowen RA. Humoral immunity to West Nile virus is long-lasting and protective in the house sparrow (Passer domesticus). Am. J. Trop. Med. Hyg. 2009;80:864–869.
    doi: 10.4269/ajtmh.2009.80.864pmc: PMC2693945pubmed: 19407139google scholar: lookup
  19. Baitchman EJ, Tlusty MF, Murphy HW. Passive transfer of maternal antibodies to West Nile virus in flamingo chicks (Phoenicopterus chilensis and Phoenicopterus ruber ruber). J. Zoo Wildl. Med. 2007;38:337–340.
    doi: 10.1638/1042-7260(2007)038[0337:ptomat]2.0.co;2pubmed: 17679521google scholar: lookup
  20. deOya NJ, Escribano-Romero E, Blazquez AB, Martin-Acebes MA, Saiz JC. Current Progress of Avian Vaccines Against West Nile Virus.. Vaccines 2019;7:126.
    doi: 10.3390/vaccines7040126pmc: PMC6963603pubmed: 31547632google scholar: lookup
  21. deOya NJ, Escribano-Romero E, Camacho MC, Blazquez AB, Martín-Acebes MA, Höfle U, Saiz JC. A Recombinant Subviral Particle-Based Vaccine Protects Magpie (Pica pica) Against West Nile Virus Infection.. Front. Microbiol. 2019;10:1133.
    doi: 10.3389/fmicb.2019.01133pmc: PMC6560071pubmed: 31231320google scholar: lookup
  22. Langevin SA, Arroyo J, Monath TP, Komar N. Host-range restriction of chimeric yellow fever-West Nile vaccine in fish crows (Corvus ossifragus). Am. J. Trop. Med. Hyg. 2003;69:78–80.
    doi: 10.4269/ajtmh.2003.69.78pubmed: 12932102google scholar: lookup
  23. Merino-Ramos T, Blázquez AB, Escribano-Romero E, Cañas-Arranz R, Sobrino F, Saiz JC, Martín-Acebes MA. Protection of a single dose west nile virus recombinant subviral particle vaccine against lineage 1 or 2 strains and analysis of the cross-reactivity with Usutu virus.. PLoS ONE 2014;9:e108056.
    doi: 10.1371/journal.pone.0108056pmc: PMC4168257pubmed: 25229345google scholar: lookup
  24. Fischer D, Angenvoort J, Ziegler U, Fast C, Maier K, Chabierski S, Eiden M, Ulbert S, Groschup MH, Lierz M. DNA vaccines encoding the envelope protein of West Nile virus lineages 1 or 2 administered intramuscularly, via electroporation and with recombinant virus protein induce partial protection in large falcons (Falco spp.). Vet. Res. 2015;46:87.
    doi: 10.1186/s13567-015-0220-1pmc: PMC4538736pubmed: 26282836google scholar: lookup
  25. Chang GJ, Davis BS, Stringfield C, Lutz C. Prospective immunization of the endangered California condors (Gymnogyps californianus) protects this species from lethal West Nile virus infection.. Vaccine 2007;25:2325–2330.
    doi: 10.1016/j.vaccine.2006.11.056pubmed: 17224209google scholar: lookup
  26. Ulbert S. West Nile virus vaccines—Current situation and future directions.. Hum. Vaccin. Immunother. 2019;15:2337–2342.
    doi: 10.1080/21645515.2019.1621149pmc: PMC6816401pubmed: 31116691google scholar: lookup
  27. Ledgerwood JE, Pierson TC, Hubka SA, Desai N, Rucker S, Gordon IJ, Enama ME, Nelson S, Nason M, Gu W. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial.. J. Infect. Dis. 2011;203:1396–1404.
    doi: 10.1093/infdis/jir054pmc: PMC3080891pubmed: 21398392google scholar: lookup
  28. Dayan GH, Pugachev K, Bevilacqua J, Lang J, Monath TP. Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus.. Viruses 2013;5:3048–3070.
    doi: 10.3390/v5123048pmc: PMC3967160pubmed: 24351795google scholar: lookup
  29. Durbin AP, Wright PF, Cox A, Kagucia W, Elwood D, Henderson S, Wanionek K, Speicher J, Whitehead SS, Pletnev AG. The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers.. Vaccine 2013;31:5772–5777.
    doi: 10.1016/j.vaccine.2013.07.064pmc: PMC3833717pubmed: 23968769google scholar: lookup
  30. Lieberman MM, Nerurkar VR, Luo H, Cropp B, Carrion R Jr, de la Garza M, Coller BA, Clements D, Ogata S, Wong T. Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys. Clin Vaccine Immunol 2009;16:1332–1337.
    doi: 10.1128/cvi.00119-09pmc: PMC2745014pubmed: 19641099google scholar: lookup
  31. Woods CW, Sanchez AM, Swamy GK, McClain MT, Harrington L, Freeman D, Poore EA, Slifka DK, Poer DeRaad DE, Amanna IJ. An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults. Vaccine 2019;37:4222–4230.
    doi: 10.1016/j.vaccine.2018.12.026pmc: PMC6640644pubmed: 30661836google scholar: lookup
  32. Barrett PN, Terpening SJ, Snow D, Cobb RR, Kistner O. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases. Expert Rev Vaccines 2017;16:883–894.
    doi: 10.1080/14760584.2017.1357471pubmed: 28724343google scholar: lookup
  33. Gould CV, Staples JE, Huang CY, Brault AC, Nett RJ. Combating West Nile Virus Disease—Time to Revisit Vaccination. N Engl J Med 2023;388:1633–1636.
    doi: 10.1056/NEJMp2301816pmc: PMC11627013pubmed: 37125778google scholar: lookup
  34. Chen RT, Shimabukuro TT, Martin DB, Zuber PL, Weibel DM, Sturkenboom M. Enhancing vaccine safety capacity globally: A lifecycle perspective. Vaccine 2015;33((Suppl S4)):D46–D54.
    doi: 10.1016/j.vaccine.2015.06.073pmc: PMC4663114pubmed: 26433922google scholar: lookup
  35. Zohrabian A, Hayes EB, Petersen LR. Cost-effectiveness of West Nile virus vaccination. Emerg Infect Dis 2006;12:375–380.
    doi: 10.3201/eid1203.050782pmc: PMC3291438pubmed: 16704772google scholar: lookup
  36. Shankar MB, Staples JE, Meltzer MI, Fischer M. Cost effectiveness of a targeted age-based West Nile virus vaccination program. Vaccine 2017;35:3143–3151.
    doi: 10.1016/j.vaccine.2016.11.078pubmed: 28456529google scholar: lookup
  37. Nasci RS, Mutebi JP. Reducing West Nile Virus Risk Through Vector Management. J Med Entomol 2019;56:1516–1521.
    doi: 10.1093/jme/tjz083pmc: PMC7092639pubmed: 31549724google scholar: lookup
  38. Bellini R, Zeller H, Van Bortel W. A review of the vector management methods to prevent and control outbreaks of West Nile virus infection and the challenge for Europe. Parasit Vectors 2014;7:323.
    doi: 10.1186/1756-3305-7-323pmc: PMC4230500pubmed: 25015004google scholar: lookup
  39. Lawler SP, Dritz DA. Effects of rice straw and water management on riceland mosquitoes. J Med Entomol 2006;43:828–832.
    doi: 10.1603/0022-2585(2006)43[828:eorsaw]2.0.co;2pubmed: 17017215google scholar: lookup
  40. Sanford MR, Chan K, Walton WE. Effects of inorganic nitrogen enrichment on mosquitoes (Diptera: Culicidae) and the associated aquatic community in constructed treatment wetlands. J Med Entomol 2005;42:766–776.
    doi: 10.1093/jmedent/42.5.766pubmed: 16363159google scholar: lookup
  41. Chaves LF, Keogh CL, Vazquez-Prokopec GM, Kitron UD. Combined sewage overflow enhances oviposition of Culex quinquefasciatus (Diptera: Culicidae) in urban areas. J Med Entomol 2009;46:220–226.
    doi: 10.1603/033.046.0206pubmed: 19351072google scholar: lookup
  42. Marten GG, Nguyen M, Mason BJ, Ngo G. Natural control of Culex quinquefasciatus larvae in residential ditches by the copepod Macrocyclops albidus. J Vector Ecol 2000;25:7–15.
    pubmed: 10925792
  43. Wilke ABB, Beier JC, Benelli G. Transgenic Mosquitoes—Fact or Fiction?. Trends Parasitol 2018;34:456–465.
    doi: 10.1016/j.pt.2018.02.003pubmed: 29526402google scholar: lookup
  44. Wilke AB, Marrelli MT. Paratransgenesis: A promising new strategy for mosquito vector control. Parasit Vectors 2015;8:342.
    doi: 10.1186/s13071-015-0959-2pmc: PMC4489152pubmed: 26104575google scholar: lookup
  45. Coleman PG, Alphey L. Genetic control of vector populations: An imminent prospect. Trop. Med. Int. Health 2004;9:433–437.
    doi: 10.1111/j.1365-3156.2004.01225.xpubmed: 15078260google scholar: lookup
  46. Thomas S, Verma J, Woolfit M, O’Neill SL. Wolbachia-mediated virus blocking in mosquito cells is dependent on XRN1-mediated viral RNA degradation and influenced by viral replication rate. PLoS Pathog 2018;14:e1006879.
    doi: 10.1371/journal.ppat.1006879pmc: PMC5833283pubmed: 29494679google scholar: lookup
  47. Dodson BL, Andrews ES, Turell MJ, Rasgon JL. Wolbachia effects on Rift Valley fever virus infection in Culex tarsalis mosquitoes. PLoS Neglected Trop. Dis. 2017;11:e0006050.
    doi: 10.1371/journal.pntd.0006050pmc: PMC5693443pubmed: 29084217google scholar: lookup
  48. Koh C, Audsley MD, Di Giallonardo F, Kerton EJ, Young PR, Holmes EC, McGraw EA. Sustained Wolbachia-mediated blocking of dengue virus isolates following serial passage in Aedes aegypti cell culture. Virus Evol 2019;5:vez012.
    doi: 10.1093/ve/vez012pmc: PMC6555872pubmed: 31191980google scholar: lookup
  49. Dodson BL, Hughes GL, Paul O, Matacchiero AC, Kramer LD, Rasgon JL. Wolbachia enhances West Nile virus (WNV) infection in the mosquito Culex tarsalis. PLoS Neglected Trop. Dis. 2014;8:e2965.
    doi: 10.1371/journal.pntd.0002965pmc: PMC4091933pubmed: 25010200google scholar: lookup
  50. Ngo T. To slow the spread of COVID-19, we need to bring back the Swiss Cheese Model of pandemic response. Health Aff. Forefr. 2021.
    doi: 10.1377/forefront.20211217.53434google scholar: lookup
  51. Shapiro H, Micucci S. Pesticide use for West Nile virus. CMAJ 2003;168:1427–1430.
    pmc: PMC155959pubmed: 12771072
  52. Coetzee BWT, Gaston KJ, Koekemoer LL, Kruger T, Riddin MA, Smit IPJ. Artificial Light as a Modulator of Mosquito-Borne Disease Risk. Front. Ecol. Evol. 2022;9:768090.
    doi: 10.3389/fevo.2021.768090google scholar: lookup
  53. Ahlers LRH, Trammell CE, Carrell GF, Mackinnon S, Torrevillas BK, Chow CY, Luckhart S, Goodman AG. Insulin Potentiates JAK/STAT Signaling to Broadly Inhibit Flavivirus Replication in Insect Vectors. Cell Rep 2019;29:1946–1960.e5.
    doi: 10.1016/j.celrep.2019.10.029pmc: PMC6871768pubmed: 31722209google scholar: lookup
  54. Trammell CE, Ramirez G, Sanchez-Vargas I, St Clair LA, Ratnayake OC, Luckhart S, Perera R, Goodman AG. Coupled small molecules target RNA interference and JAK/STAT signaling to reduce Zika virus infection in Aedes aegypti. PLoS Pathog 2022;18:e1010411.
    doi: 10.1371/journal.ppat.1010411pmc: PMC9017935pubmed: 35377915google scholar: lookup
  55. Chirico F, Magnavita N. The West Nile virus epidemic-occupational insight. Lancet 2019;393:1298.
    doi: 10.1016/s0140-6736(19)30028-5pubmed: 30938316google scholar: lookup
  56. Burki T. Increase of West Nile virus cases in Europe for 2018. Lancet 2018;392:1000.
    doi: 10.1016/s0140-6736(18)32286-4pubmed: 30264694google scholar: lookup
  57. Odigie AE, Stufano A, Schino V, Zarea AAK, Ndiana LA, Mrenoshki D, Ugochukwu ICI, Lovreglio P, Greco G, Pratelli A. West Nile Virus Infection in Occupational Settings-A Systematic Review. Pathogens 2024;13:157.
    doi: 10.3390/pathogens13020157pmc: PMC10892351pubmed: 38392895google scholar: lookup
  58. Meghani Z. Regulation of genetically engineered (GE) mosquitoes as a public health tool: A public health ethics analysis.. Glob. Health 2022;18:21.
    doi: 10.1186/s12992-021-00760-xpmc: PMC8862287pubmed: 35189901google scholar: lookup
  59. James SL, Dass B, Quemada H. Regulatory and policy considerations for the implementation of gene drive-modified mosquitoes to prevent malaria transmission.. Transgenic Res 2023;32:17–32.
    doi: 10.1007/s11248-023-00335-zpmc: PMC10102045pubmed: 36920721google scholar: lookup

Citations

This article has been cited 15 times.
  1. Nistor P, Stanga L, Chirila A, Iorgoni V, Gligor A, Ciresan A, Florea B, Bota C, Cocioba V, Popa I, Orghici G, Iancu I, Maris CH, Degi J, Herman V. Mosquito Exposure Risks in Equine Facilities: An Environmental-Managerial Assessment in Western Romania.. Microorganisms 2025 Nov 20;13(11).
    doi: 10.3390/microorganisms13112637pubmed: 41304321google scholar: lookup
  2. Alibekova DA, Barakbayev KB, Omarova ZD, Rystaeva RA, Sultankulova KT, Burashev YD, Argimbayeva TU, Tulendibayev AB, Aubakir NA, Yermekbay TT, Abeuov KB, Kerimbayev AA, Orynbayev MB. Serological Investigations on West Nile Virus in Horses in Kazakhstan.. Microorganisms 2025 Nov 6;13(11).
    doi: 10.3390/microorganisms13112541pubmed: 41304226google scholar: lookup
  3. Güner AE, Küçükoğlu MB, Aktura B, Kıran P. Epidemiological and clinical characteristics of West Nile virus infections in Istanbul, Türkiye: a population-based cohort study.. BMC Infect Dis 2025 Nov 17;25(1):1603.
    doi: 10.1186/s12879-025-12019-6pubmed: 41249944google scholar: lookup
  4. Abbas I, Ahmed F, Muqaddas H, Alberti A, Varcasia A, Sedda L. Epidemiology and surveillance of West Nile virus in the Mediterranean Basin during 2010-2023: A systematic review.. Curr Res Parasitol Vector Borne Dis 2025;7:100277.
    doi: 10.1016/j.crpvbd.2025.100277pubmed: 40586111google scholar: lookup
  5. Ardakani RV, Crane PD, Pastula DM, Chauhan L, Matthews E, Money KM, Shah A, Piquet AL, Gross RH, Carlson AM, Tyler KL, Corboy JR, Alvarez E, Wolf AB. West Nile Virus Neuroinvasive Disease in Patients Treated With Anti-CD20 Therapies.. Neurol Clin Pract 2025 Aug;15(4):e200489.
    doi: 10.1212/CPJ.0000000000200489pubmed: 40584641google scholar: lookup
  6. Fautt C, Boudreau MR, Mooney AC, Cohnstaedt LW, Hudson AR, Humphreys JM. The emergence of NY10: insights into the 2012 West Nile Virus outbreak in the United States.. Virus Evol 2025;11(1):veaf037.
    doi: 10.1093/ve/veaf037pubmed: 40574749google scholar: lookup
  7. Kocabiyik DZ, Álvarez LF, Durigon EL, Wrenger C. West Nile virus - a re-emerging global threat: recent advances in vaccines and drug discovery.. Front Cell Infect Microbiol 2025;15:1568031.
    doi: 10.3389/fcimb.2025.1568031pubmed: 40444156google scholar: lookup
  8. Levasseur A, Paré J, Aubry P, Iwasawa S, Leung D, Arsenault J. Stochastic modeling of the horse population and vaccination data indicates low annual vaccination coverage for West Nile virus in Canada (2016-2020).. Can J Vet Res 2025 Apr;89(2):54-63.
    pubmed: 40170915
  9. Carrasco L, Utrilla MJ, Fuentes-Romero B, Fernandez-Novo A, Martin-Maldonado B. West Nile Virus: An Update Focusing on Southern Europe.. Microorganisms 2024 Dec 18;12(12).
    doi: 10.3390/microorganisms12122623pubmed: 39770826google scholar: lookup
  10. Aleksashin NA, Langeberg CJ, Shelke RR, Yin T, Cate JHD. RNA elements required for the high efficiency of West Nile virus-induced ribosomal frameshifting.. Nucleic Acids Res 2025 Jan 24;53(3).
    doi: 10.1093/nar/gkae1248pubmed: 39698810google scholar: lookup
  11. Singh P, Khatib MN, Ballal S, Kaur M, Nathiya D, Sharma S, Prasad GVS, Sinha A, Gaidhane AM, Mohapatra P, Varma A, Lakhanpal S, Shabil M, Bushi G, Sah S, Abu Serhan H. West Nile Virus in a changing climate: epidemiology, pathology, advances in diagnosis and treatment, vaccine designing and control strategies, emerging public health challenges - a comprehensive review.. Emerg Microbes Infect 2025 Dec;14(1):2437244.
    doi: 10.1080/22221751.2024.2437244pubmed: 39614679google scholar: lookup
  12. Dinu S, Stancu IG, Cotar AI, Ceianu CS, Pintilie GV, Karpathakis I, Fălcuță E, Csutak O, Prioteasa FL. Continuous and Dynamic Circulation of West Nile Virus in Mosquito Populations in Bucharest Area, Romania, 2017-2023.. Microorganisms 2024 Oct 17;12(10).
    doi: 10.3390/microorganisms12102080pubmed: 39458389google scholar: lookup
  13. Álvarez-Mínguez A, Del Río N, Belén-Blázquez A, Casanova E, Orduña JM, Camarero P, Hurtado-Marcos C, Del Águila C, Pérez-Pérez MJ, Martín-Acebes MA, Agudo R. Development of a luminescence-based method for measuring West Nile Virus MTase activity and its application to screen for antivirals.. Curr Res Microb Sci 2024;7:100282.
    doi: 10.1016/j.crmicr.2024.100282pubmed: 39445035google scholar: lookup
  14. Branda F, Giovanetti M, Ceccarelli G, Ciccozzi M, Scarpa F. ArboItaly: Leveraging open data for enhanced arbovirus surveillance in Italy.. Front Pharmacol 2024;15:1459408.
    doi: 10.3389/fphar.2024.1459408pubmed: 39376616google scholar: lookup
  15. Li L, Li S, Ma H, Akhtar MF, Tan Y, Wang T, Liu W, Khan A, Khan MZ, Wang C. An Overview of Infectious and Non-Infectious Causes of Pregnancy Losses in Equine.. Animals (Basel) 2024 Jul 2;14(13).
    doi: 10.3390/ani14131961pubmed: 38998073google scholar: lookup
Subscribe to our newsletter
Join 99,075 horse owners like you who receive our email updates on horse health and nutrition.